PeerVoice Oncology & Haematology Audio

PeerVoice is an independent, professional medical publishing concern focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerVoice Publications, PeerVoice is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes.

http://www.peervoice.com

Eine durchschnittliche Folge dieses Podcasts dauert 19m. Bisher sind 234 Folge(n) erschienen. Dieser Podcast erscheint wöchentlich.

Gesamtlänge aller Episoden: 4 days 11 minutes

subscribe
share





What's on the Radio? 2021 Data Broadcast on Radioligands in Men With CRPC


What's on the Radio? 2021 Data Broadcast on Radioligands in Men With CRPC


share







 2021-07-22  18m
 
 

Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses


Expanding Treatment Options in MET Exon 14-Skipping NSCLC: Clinical Insights From 2021 Virtual Congresses


share







 2021-07-16  8m
 
 

Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?


Immunotherapies for Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Which Antibodies for Which Patients?


share







 2021-07-13  58m
 
 

Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?


Checkpoint Inhibitors for Advanced or Recurrent Endometrial Cancer: A New Standard of Care?


share







 2021-06-26  26m
 
 

Radioligand Therapy in mCRPC: A Team Effort


Radioligand Therapy in mCRPC: A Team Effort


share







 2021-06-25  29m
 
 

Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold


Advanced Basal Cell Carcinoma: An Exploration of Clinical Challenges and What the Future Could Hold


share







 2021-06-22  58m
 
 

Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do


"Improving Outcomes in Early-Stage EGFR-Mutant NSCLC: What Pathologists Can Do"


share







 2021-06-12  13m
 
 

Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer


Asked and Answered: Differentiating Between PARP Inhibitors in First-Line Advanced Ovarian Cancer


share







 2021-05-21  27m
 
 

Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists


Evolving Treatment Paradigm in Early-Stage EGFR-Mutant NSCLC: A Primer for Medical Oncologists


share







 2021-05-12  16m
 
 

Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists


Best Practices in Early-Stage EGFR-Mutant NSCLC: A Primer for Radiation Oncologists


share







 2021-05-11  18m